Valneva Announces its Intention to Delist from the Vienna Stock Exchange

Trading will be centralized on Euronext Paris

Valneva SE (“Valneva”), a biotech company developing and commercializing vaccines for infectious diseases with major unmet needs, announced today that it intends to delist from the Vienna Stock Exchange (VSE) in order to focus on the best capital markets for life science companies and increase liquidity by centralizing trading on Euronext Paris.

Valneva’s ordinary shares have been listed on the VSE since May 28, 2013 and admitted to trade on the Official Market (Amtlicher Handel) in the Prime Market (ISIN FR0004056851). They are further listed on Euronext Paris (compartment B) where they will continue to trade. Valneva’s preferred shares (ISIN FR0011472943) are traded on the VSE’s Third Market Segment (MTF) and on Euronext Paris.

Valneva has a significant operational center in Vienna, including a major research and development hub along with several other functions, which will continue to develop and play an essential role in global operations as the Company continues to grow. The delisting of Valneva shares from the VSE has been approved by the Company’s supervisory and management boards and will be submitted for shareholder voting at the Company’s annual general meeting (AGM), to take place on June 27, 2019. Shareholders will be requested to resolve on the revocation of the admission of Valneva’s ordinary shares from the Official Market of the VSE, according to §38 (6) of the Austrian Stock Exchange Act 2018.

Subject to AGM approval, the application to delist Valneva’s ordinary shares will be filed with the VSE after the AGM. The VSE will then have ten weeks to decide on the application and timeline of the delisting. A period of at least three months between the publication of VSE’s decision and the effective date of the delisting is required, which potentially places the effective delisting date in the fourth quarter of 2019. In addition to the delisting of the ordinary shares, Valneva’s management board has decided to terminate the trading of the preferred shares on the Third Market (MTF) segment of the VSE. The trading of Valneva’s preferred shares on the MTF shall terminate in parallel with that of the ordinary shares.

David Lawrence, Valneva’s Chief Financial Officer, commented, “We would like to thank all of our long-term Austrian shareholders for their continued support and encourage them to trade on Euronext Paris, which is an excellent platform for biotech stocks in Europe. Vienna will continue to be an essential operational hub, but we need to focus on the best capital markets for life sciences to support our ambitious growth plans. We strongly believe that this decision benefits shareholders in the long run.”

For further information please visit or contact the Investor Relations department in Vienna directly by phone: +43-1-20620-1116 or email


FR0004056851 (ordinary shares), FR0011472943 (preferred shares)

Stock exchanges

Official Market (Prime Market) Vienna Stock Exchange;
Compartment B Euronext Paris, France

About Valneva SE

Valneva is a biotech company developing and commercializing vaccines for infectious diseases with major unmet needs. Valneva’s portfolio includes two commercial vaccines for travelers: IXIARO®/JESPECT® indicated for the prevention of Japanese encephalitis and DUKORAL® indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by ETEC. The Company has a robust pipeline of vaccines in development including a unique vaccine against Lyme disease. Valneva has operations in Austria, Sweden, the United Kingdom, France, Canada and the US with over 450 employees. More information is available at

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)